Telesis Bio (TBIO)
OTHER OTC:TBIO
Top Page
No summary available
Positive Factors
Innovative Product Offering
The company's focus on cutting-edge DNA synthesis technologies positions it well in the growing synthetic biology market, providing a durable competitive advantage.
Negative Factors
High Leverage
Heavy reliance on debt financing increases financial risk and limits flexibility, potentially impacting long-term sustainability if not managed properly.
Read all positive and negative factors
Positive Factors
Negative Factors
Innovative Product Offering
The company's focus on cutting-edge DNA synthesis technologies positions it well in the growing synthetic biology market, providing a durable competitive advantage.
Read all positive factors
Telesis Bio (TBIO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.00M
Dividend YieldN/A
Average Volume (3M)271.00
Price to Earnings (P/E)―
Beta (1Y)0.99
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees39
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)N/A
Shares Outstanding78,393,530
10 Day Avg. Volume61
30 Day Avg. Volume271
Financial Highlights & Ratios
PEG Ratio1.24
Price to Book (P/B)7.28
Price to Sales (P/S)7.81
P/FCF Ratio-5.86
Enterprise Value/Market Cap9.21
Enterprise Value/Revenue2.72
Enterprise Value/Gross Profit8.04
Enterprise Value/Ebitda-0.96
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Telesis Bio Business Overview & Revenue Model
Company Description
Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioX...
How the Company Makes Money
Telesis Bio makes money primarily through the sale of its DNA synthesis technologies and related services. The company's revenue streams include sales of its proprietary synthetic biology platforms that allow customers to design and synthesize DNA...
Telesis Bio Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 13.53M | 27.51M | 27.43M | 11.04M | 6.58M | 4.80M |
| Gross Profit | 4.58M | 16.95M | 15.60M | 4.30M | 3.63M | -4.08M |
| EBITDA | -38.48M | -40.49M | -43.62M | -36.00M | -15.86M | -5.96M |
| Net Income | -45.55M | -47.72M | -48.47M | -38.96M | -18.01M | -8.30M |
Balance Sheet | ||||||
| Total Assets | 24.74M | 70.41M | 81.36M | 116.26M | 26.86M | 38.76M |
| Cash, Cash Equivalents and Short-Term Investments | 4.51M | 19.16M | 43.75M | 82.81M | 13.46M | 29.14M |
| Total Debt | 16.29M | 34.38M | 21.43M | 17.32M | 8.33M | 4.77M |
| Total Liabilities | 20.86M | 40.87M | 34.80M | 25.47M | 52.32M | 46.26M |
| Stockholders Equity | 3.87M | 29.54M | 46.56M | 90.78M | -25.46M | -7.50M |
Cash Flow | ||||||
| Free Cash Flow | -23.74M | -36.65M | -43.18M | -38.55M | -15.59M | -6.47M |
| Operating Cash Flow | -22.85M | -34.67M | -38.72M | -36.70M | -15.38M | -6.39M |
| Investing Cash Flow | 24.32M | -5.74M | -18.01M | -15.04M | -204.00K | -79.00K |
| Financing Cash Flow | -15.22M | 11.56M | 4.51M | 121.08M | -96.00K | 35.11M |
Telesis Bio Technical Analysis
Negative
0.05
Price Trends
0.05
Negative
0.05
Positive
0.05
Negative
Market Momentum
>-0.01
Negative
30.89
Neutral
<0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TBIO, the sentiment is Negative. The current price of 0.05 is above the 20-day moving average (MA) of 0.05, below the 50-day MA of 0.05, and below the 200-day MA of 0.05, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 30.89 is Neutral, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TBIO.
Telesis Bio Risk Analysis
Telesis Bio disclosed 76 risk factors in its most recent earnings report. Telesis Bio reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Telesis Bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $4.00M | ― | -175.00% | ― | ― | ― | |
60 Neutral | $66.77M | 22.00 | 10.27% | ― | 16.88% | ― | |
46 Neutral | $96.84M | -2.75 | -68.83% | ― | 16.63% | 10.43% | |
46 Neutral | $23.18M | -2.62 | -221.04% | ― | -18.96% | 8.98% | |
44 Neutral | $36.69M | -4.85 | -91.54% | ― | -8.97% | 47.29% | |
44 Neutral | $25.07M | -1.43 | -441.55% | ― | 12.24% | 47.45% |
* Healthcare Sector Average
TBIO
Telesis Bio
0.05
-0.71
-93.29%
CTSO
Cytosorbents
0.59
-0.42
-41.68%
XTNT
Xtant Medical Holdings
0.51
0.12
30.77%
TELA
TELA Bio
0.60
-0.40
-39.80%
RPID
Rapid Micro Biosystems
2.19
-0.09
-3.95%
ICCM
Icecure Medical
0.35
-0.75
-67.82%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―